Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

NCT01754376 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped changes in available treatments for melanoma

Conditions

Melanoma

Interventions

DRUG: Aldesleukin
DRUG: Vemurafenib

Sponsor

Massachusetts General Hospital